Latest Breaking News On - Merus dock - Page 1 : comparemela.com

Merus Announces U S FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC

If approved, Zeno will be the first targeted therapy for NRG1+ cancerUTRECHT, The Netherlands and CAMBRIDGE, Mass., May 06, 2024 Merus N.V. , a clinical-stage oncology company developing.

United statesUnited kingdomAndrew joeExchange commissionDrug administrationEuropean society for medical oncologyAmerican society of clinical oncologyBiologics license applicationChief medical officerAmerican societyClinical oncologyEuropean societyMedical oncologyBreakthrough therapy designationMerus dockPrivate securities litigation reform act

Merus N V (MRUS) Announces U S FDA Acceptance and Priority Review of Biologics License Application for Zeno

Merus N V (MRUS) Announces U S FDA Acceptance and Priority Review of Biologics License Application for Zeno
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAndrew joeAmerican society of clinical oncologyExchange commissionEuropean society for medical oncologyDrug administrationBiologics license applicationChief medical officerAmerican societyClinical oncologyEuropean societyMedical oncologyBreakthrough therapy designationMerus dockPrivate securities litigation reform actAnnual report

Merus N V : Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024

Merus N V : Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomXand linkedinCecile geuijenDennis riedlExchange commissionAmerican association of cancer researchAmerican associationCancer researchAnnual meetingChief scientific officerMerus dockPrivate securities litigation reform actAnnual report

2023-10-23 | NDAQ:MRUS | Press Release

(2023-10-23 | NDAQ:MRUS) Merus' Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer

United kingdomAndrew joeAlison schramZeno closecurlyquoteEarly access programMemorial sloan kettering cancer centerCorporate communicationsExchange commissionEuropean society for medical oncologyCompany closecurlydoublequotePrincipal investigatorEuropean societyMedical oncologyChief medical officerMerus closecurlyquoteMerus dock

Merus Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer -October 23, 2023 at 07:31 am EDT

- 37% ORR and 14.9 months median DOR in 78 evaluable NRG1+ NSCLC patients - 42% ORR and 9.1 months median DOR in 33 evaluable NRG1+ PDAC patients - Sufficient clinical data expected in 1H24 to.

United kingdomAndrew joeAlison schramExchange commissionEarly access programMemorial sloan kettering cancer centerEuropean society for medical oncologyPrincipal investigatorEuropean societyMedical oncologyChief medical officerMerus dockPrivate securities litigation reform actQuarterly report